Facial aesthetics: Is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials

British Dental Journal

Volumn 207, Issue 5, 2009, Pages

  Gadhia, K ^a   Walmsley, A D ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BIRMINGHAM DENTAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTHETICS; FACE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REJUVENATION; REVIEW;

BLEPHAROPTOSIS; BOTULINUM TOXINS, TYPE A; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTHETICS; FACE; HUMANS; INJECTIONS, INTRAMUSCULAR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REJUVENATION;

EID: 84984777662     PISSN: 00070610     EISSN: 17417503     Source Type: Journal    
DOI: 10.1038/sj.bdj.2009.813     Document Type: Article

References (23)

1. Truong D D, Jost W H. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006; 12: 331-355.
2. Kostrzewa R M, Segura-Aguilar J. Botulinum neurotoxin: evolution from poison, to research tool - onto medicinal therapeutic and future pharmaceutical panacea. Neurotox Res 2007; 12: 275-290.
3. Bhogal P S, Hutton A, Monaghan A. A review of the current uses of botox for dentally-related procedures. Dent Update 2006; 33: 165-168.
4. Ansiaux R, Gallez B. Use of botulinum toxins in cancer therapy. Expert Opin Investig Drugs 2007; 16: 209-218.
5. Wise J B, Greco T. Injectable treatments for the aging face. Facial Plast Surg 2006; 22: 140-146.
6. Coleman S R, Grover R. The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J 2006; 26(1S): S4-S9.
7. Fedok F G. Advances in minimally invasive facial rejuvenation. Curr Opin Otolaryngol Head Neck Surg 2008; 16: 359-368.
8. Independent Healthcare Advisory Services. Standards for injectable cosmetic treatments. London: Independent Healthcare Advisory Services, 2008. Available online at www.independenthealthcare.org.uk (accessed 1 January 2009).
9. NHS Public Health Resource Unit. Appraisal tools webpage.http://www.phru. nhs.uk/Pages/PHD/resources.htm (accessed 10 January 2009).
10. Higgins J P T, Green S (eds). Cochrane handbook for systematic reviews of interventions. cochrane-handbook.org/ (accessed 10 January 2009).
11. Lowe N J, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N; Botox Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and effi cacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257-262.
12. Carruthers J A, Lowe N J, Menter M A et al.; BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840-849.
13. Carruthers J D, Lowe N J, Menter M A et al. Doubleblind, placebo controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112: 1089-1098.
14. Rzany B, Ascher B, Fratila A, Monheit G, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320-326.
15. Ascher B, Zakine B, Kestemont P et al. A multicenter, randomized, double-blind, placebo controlled study of efficacy and safety of 3 doses of botulinum toxin A in the trearment of glabellar lines. J Am Acad Dermatol 2004; 51: 223-233.
16. Lowe N J, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized, comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002; 47: 834-840.
17. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33(1 Spec No.): S51-S59.
18. Fagien S, Cox S E, Finn J C, Werschler P, Kowalski J W. Patient reported outcomes with botulinum toxin type A treatment of glabellar rhytids. A double blind, randomised, placebo-controlled study. Dermatol Surg 2007; 33(1 Spec No.): S2-S9.
19. Lowe N J, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996; 35: 569-572.
20. Keen M, Blitzer A, Aviv J et al. Botulinum toxin A for hyperkinetic facial lines: results of a double blind, placebo controlled study. Plast Reconstr Surg 1994; 94: 94-99.
21. Beer K, Yohn M, Closter J. A double-blinded, placebo- controlled study of Botox for the treatment of subjects with chin rhytids. J Drugs Dermatol 2005; 4: 417-422.
22. Jadad A R, Moore R A, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
23. Sampaio C, Costa J, Ferreira J J. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19(Suppl 8): S129-S136.